<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antithymocyte globulin (ATG) therapy is an established form of treatment for aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> and has also been used as prophylaxis against graft rejection of bone marrow and renal allografts </plain></SENT>
<SENT sid="1" pm="."><plain>Administration of ATG preparations has been associated with many mild clinical reactions, as have other forms of immunomodulatory therapy </plain></SENT>
<SENT sid="2" pm="."><plain>However, serious adverse effects appear to be rare </plain></SENT>
<SENT sid="3" pm="."><plain>We report a case of <z:hpo ids='HP_0003678'>rapidly progressive</z:hpo> fibrosing <z:mp ids='MP_0010922'>alveolitis</z:mp> and <z:e sem="disease" ids="C0040156" disease_type="Disease or Syndrome" abbrv="">thyrotoxicosis</z:e> in relation to ATG therapy, highlighting its potential toxicity and emphasising that its administration should be undertaken by experienced physicians in specialised centres </plain></SENT>
</text></document>